

PREPRESS - INFORMATION

Format 53 x 64 x 87 mm
Register Nr. 10.609
NP 1830
18.03.2026 09:51:49
Grundschrift 8 Punkt

PREPRESS - ROCHE BASEL

Control Proof
 Date:

New Proof
 Date:

11028452 MY
 FILM 1 VON 5
 Pantone Black
 18.03.26

11028452 MY
 FILM 2 VON 5
 PMS 2388
 18.03.26

11028452 MY
 FILM 3 VON 5
 PMS 485
 18.03.26

11028452 MY
 FILM 4 VON 5
 PMS 7456
 18.03.26

11028452 MY
 FILM 5 VON 5
 PMS 151
 18.03.26

Roche
 1 vial of 23 mL solution for injection
 For subcutaneous use only
920 mg/23 mL
Ocrevus®
 solution for injection
 ocrelizumab

One vial contains 920 mg of ocrelizumab in 23 mL solution. Also contains: recombinant human hyaluronidase (rHuPH20), sodium acetate trihydrate, glacial acetic acid, α,α-trehalose dihydrate, polysorbate 20, L-methionine, water for injections.

For subcutaneous injection use only
 Keep medicine out of reach of children
 Dosage and administration: see package insert
 Store in a refrigerator (2°C-8°C). Do not freeze. Do not shake. Keep vial in the outer carton in order to protect from light

Ubat terkawal / Controlled Medicine
 Jauhkan daripada capaian kanak-kanak

Manufactured by Roche Diagnostics GmbH Mannheim, Germany
 Released by F. Hoffmann-La Roche Ltd., Kaiseraugst, Switzerland
 Importer/Product Registration Holder: Roche (Malaysia) Sdn. Bhd., Level 21, The Pinnacle, Persiaran Lagoon, Bandar Sunway, 47500 Subang Jaya, Selangor, Malaysia

Malaysia: MAL26036011ARZ

Ocrevus®
 solution for injection
 ocrelizumab
920 mg/23 mL
 For subcutaneous use only
 1 vial of 23 mL solution for injection
Roche

Ocrevus®
 solution for injection
 ocrelizumab
920 mg/23 mL
 For subcutaneous use only
 1 vial of 23 mL solution for injection
Roche

GTIN (01) 07613326078061
 SN (21)
 EXP
 LOT (10)
 MFD